For chronic back pain, a disc treatment relieved pain for 60% of patients — while the sham helped almost none

Low back pain is the world's leading cause of disability, and for people whose pain comes from a worn spinal disc, the choices have long been stark: cope, take long-term painkillers, or face major surgery. Results from the pivotal ASCEND trial of VIA Disc NP, published in the Journal of Clinical Medicine, offer a different path: a minimally invasive injection of disc tissue material, given under light sedation in an outpatient visit. At six months, 60% of treated participants had clinically meaningful pain relief, compared with 1.6% of those who received a sham procedure — and the gap was already clear at three months, while everyone was still blinded. It is the first treatment of its kind to succeed in a rigorous sham-controlled trial.

SDG 3 · Good health and well-being — Mechanism: tech innovation